ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 2388 for:    parkinson's

Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease (HALLUPARK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03105401
Recruitment Status : Recruiting
First Posted : April 10, 2017
Last Update Posted : February 19, 2018
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

This study aims to describe hallucinations prevalence in a sample of patients affected by Parkinson's disease and consulting in an outpatient facility.

An unique one hour interview will be offered to volunteers patients. Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.

The study hypothesis is that hallucinations prevalence in Parkinson's disease is underestimated and is higher than usually described in the scientific literature when all hallucinations modalities and minor hallucinatory phenomenons are searched for.


Condition or disease Intervention/treatment
Parkinson Disease Other: Assessment of hallucinations in Parkinson's disease

Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease
Actual Study Start Date : May 15, 2017
Estimated Primary Completion Date : January 15, 2019
Estimated Study Completion Date : January 15, 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patients affected by Parkinson's disease
Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
Other: Assessment of hallucinations in Parkinson's disease
Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.




Primary Outcome Measures :
  1. Hallucinations Prevalence [ Time Frame: 1 hour ]

    Semi-structured questionnaire precisely describing hallucinations of all modalities and their characteristics, as well as minor hallucinations and delusions. Binary Yes/No possible answers.

    Unique 1 hour interview to assess semi-structured questionnaire for primary outcome measurement, and psychometric scales.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
Criteria

Inclusion Criteria:

  • Age ≥ 18 years-old
  • Absence of opposition from the patient himself/herself or his/her legal representant for his/her participation to the study
  • Patient without superior age limit with a diagnosis of Parkinson's disease made according to the UKPDSBB criteria (UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria)
  • Outpatient consulting in neurology at the Charpennes'hospital

Exclusion Criteria:

  • Opposition to the study
  • Deafness or blindness which could compromise the interview

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03105401


Contacts
Contact: Jing XIE, MD 04 72 43 20 54 ext +33 jing.xie@chu-lyon.fr
Contact: Claire MOUTET 04 72 43 22 50 ext +33 claire.moutet@chu-lyon.fr

Locations
France
Hôpital des Charpennes. Centre de Recherche Clinique - vieillissement, cerveau, fragilité Recruiting
Villeurbanne, France, 69100
Contact: Jing XIE, MD    04 72 43 20 54 ext +33    jing.xie@chu-lyon.fr   
Contact: Claire MOUTET    04 72 43 22 50 ext +33    claire.moutet@chu-lyon.fr   
Principal Investigator: Jing XIE, MD         
Sub-Investigator: Mathilde BONZE, MD         
Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Principal Investigator: Jing XIE, MD Hôpital des Charpennes. Centre de Recherche Clinique - vieillissement, cerveau, fragilité

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT03105401     History of Changes
Other Study ID Numbers: 69HCL17_0137
First Posted: April 10, 2017    Key Record Dates
Last Update Posted: February 19, 2018
Last Verified: April 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Parkinson Disease
Hallucinations
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Perceptual Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms